Virtual Network's Login.
About the Conference:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies will also be discussed.
CONFERENCE MAIN SCIENTIFIC TOPICS:
- Non-hodgkin lymphoma (NHL)
- Multiple myeloma
- Novel indications CAR T-cell therapy
- Managing toxicity of CAR-T and bispecific antibody treatment
- Real world data CAR-T
- Life after CAR T-cell therapy
LEARNING OBJECTIVES:
Upon completion of this CME activity, participants should be able to:
- Understanding of the current landscape of bispecific antibodies in NHL, MM and ALL
- Understanding of the current landscape of CAR-T cell therapy in NHL, MM and ALL
- Novel approaches and technologies in the field
- Integration of novel therapies into current clinical practice
- Understanding the management of side effects of CAR T-cell therapy
and bispecific antibodies
- Understand potential indications and sequencing of CAR-T cells and bispecifics
With the support of*:
Major Conference Partner
*******
Supporting Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.
